Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nutramax Laboratories, Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, showing a varied technical distribution within the pharmaceutical sector. The presence of 3 pending office actions indicates that the company is actively pursuing multiple distinct innovations within the biotechnology field.
The company's prosecution involves 3 distinct examiners. CHEN, CATHERYNE is the busiest examiner for Nutramax Laboratories, Inc., currently managing 1 pending office action. The presence of 3 distinct examiners and 3 distinct art units for 3 pending office actions indicates that each of the company's current applications is being reviewed in a separate specialized area of the patent office. This ensures that each matter is evaluated by an examiner with specific expertise in the relevant art unit.
For practitioners, this distribution across 3 distinct examiners and 3 distinct art units means that prosecution strategies must be tailored to the specific expectations of each individual examiner. There is no central examiner handling multiple matters, which may lead to independent outcomes for each application. The focus on Biotechnology & Pharmaceuticals remains the unifying theme across these diverse prosecution paths, with CHEN, CATHERYNE handling one of the matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.8% |
| PIHONAK, SARAH | 1 | 61.3% | +42.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717197 | SUPPLEMENTAL COATING AND RELATED METHOD | BERRIOS, JENNIFER A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18767447 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER | CHEN, CATHERYNE | — |
| 18717197 | SUPPLEMENTAL COATING AND RELATED METHOD | BERRIOS, JENNIFER A | — |
| 18644758 | COMPOSITIONS COMPRISING HYDROXYTYROSOL AND BOSWELLIC ACID | PIHONAK, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767447 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER | CHEN, CATHERYNE | 1655 | §102§103DP | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18717197 | SUPPLEMENTAL COATING AND RELATED METHOD | BERRIOS, JENNIFER A | 1613 | §102§103 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18644758 | COMPOSITIONS COMPRISING HYDROXYTYROSOL AND BOSWELLIC ACID | PIHONAK, SARAH | 1627 | DP | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial